Repligen Stock News

Regeneron, Vertex Pharmaceuticals, Dynavax Technologies Corp. and Repligen are highlighted in this Industry Outlook article.

New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position VRTX, REGN, DVA

Style Box ETF report for RFG

These two companies offer under-the-radar ways to invest in the healthcare space.

The FDA agrees to the initiation of rolling submission of Gamida's (GMDA) BLA for its lead blood cancer candidate, omidubicel. The stock rises more than 22% on in response.

Style Box ETF report for IVOG

Smart Beta ETF report for PBE

And they're built to remain among the world's fastest-growing companies as well.

The European Commission approves Vertex's (VRTX) triple combination therapy, Kaftrio, in combination with Kalydeco for treating cystic fibrosis in children aged between six and 11 years.

Repligen (RGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising

Repligen (RGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising

Repligen Corp. (RGEN) shares closed this week 21.9% lower than it did at the end of last week. The stock is currently down 21.9% year-to-date, down 0.8% over the past 12 months, and up 524.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $265.78 and as low as $204.10 this week.Shares closed 36.8% below its 52-week high and 27.4% above its 52-week low.Trading volume this week was 13.1% higher than the 10-day average and 57.8% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 190.2% The company's stock price performance over the past 12 months lags the peer average by -117.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 12.0% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Commodities were the only major index to gain ground last week. Read here for a detailed review...

Acadia Healthcare (ACHC) is poised for growth due to higher revenues driven by solid demand for behavioral health services, multiple JVs with established healthcare systems and debt repayment efforts.

J&J (JNJ) submits a Biologics License Application, seeking approval for its bispecific antibody candidate teclistamab as a treatment option for the heavily pretreated multiple myeloma patients.